drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Recombinant humanized monoclonal antibody targeting Claudin 18.2 (CLDN18.2); promotes antitumor activity via direct tumor cell targeting and immune effector mechanisms such as ADCC and CDC.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody targeting Claudin 18.2 on tumor cells; induces immune-mediated tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) after binding to CLDN18.2-expressing cells.
drug_name
TST001
nct_id_drug_ref
NCT06093425